Aytu BioPharma: From Loss to Profit in 2 Years with 99% Growth Rate

Aytu BioPharma, a pharmaceutical company, is expected to breakeven in 2028, two years from today, with an average annual growth rate of 99%. However, its high debt-to-equity ratio of 147% increases the risk of investing. The company's path to profitability is crucial for investors, and its future prospects are expected to be driven by underlying developments in drug development.